{
    "xml": "<topic id=\"PHP2220\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/flupentixol\" basename=\"flupentixol\" title=\"FLUPENTIXOL\">\n<title>FLUPENTIXOL</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_389\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/thioxanthenes/flupentixol\">Flupentixol</xref>\n</p>\n<data name=\"vtmid\">13314611000001107</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_182743901\" title=\"Antipsychotics (first-generation)\">Antipsychotics (first-generation)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" title=\"ANTIPSYCHOTIC DRUGS\" namespace=\"/drug-classes/antipsychotic-drugs\">ANTIPSYCHOTIC DRUGS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n<p outputclass=\"synonyms\">Flupenthixol</p>\r\n</body>\n<topic id=\"PHP60420\" outputclass=\"indicationsAndDose\" rev=\"1.25\" parent=\"/drugs/flupentixol\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Schizophrenia and other psychoses, particularly with apathy and withdrawal but not mania or psychomotor hyperactivity</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 3&#8211;9&#8239;mg twice daily, adjusted according to response, for debilitated patients, use elderly dose; maximum 18&#8239;mg per day.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Initially 0.75&#8211;4.5&#8239;mg twice daily, adjusted according to response.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Depressive illness</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 1&#8239;mg once daily, dose to be taken in the morning, increased if necessary to 2&#8239;mg after 1&#8239;week, doses above 2&#8239;mg to be given in divided doses, last dose to be taken before 4 pm; discontinue if no response after 1 week at maximum dosage; maximum 3&#8239;mg per day.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Initially 500&#8239;micrograms daily, dose to be taken in the morning, then increased if necessary to 1&#8239;mg after 1&#8239;week, doses above 1&#8239;mg to be given in divided doses, last dose to be taken before 4 pm; discontinue if no response after 1 week at maximum dosage; maximum 1.5&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60491\" outputclass=\"contraindications\" rev=\"1.20\" parent=\"/drugs/flupentixol\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Circulatory collapse</ph>; <ph outputclass=\"contraindication\">CNS depression</ph>; <ph outputclass=\"contraindication\">comatose states</ph>; <ph outputclass=\"contraindication\">excitable patients</ph>; <ph outputclass=\"contraindication\">impaired consciousness</ph>; <ph outputclass=\"contraindication\">overactive patients</ph>; <ph outputclass=\"contraindication\">phaeochromocytoma</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60514\" outputclass=\"cautions\" rev=\"1.28\" parent=\"/drugs/flupentixol\">\n<title>Cautions</title>\n<body>\r\n<section outputclass=\"cautions\">\r\n<p>\r\n<ph outputclass=\"caution\">\r\n<xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>; <ph outputclass=\"caution\">cardiac disorders</ph>; <ph outputclass=\"caution\">cardiovascular disease</ph>; <ph outputclass=\"caution\">cerebral arteriosclerosis</ph>; <ph outputclass=\"caution\">diabetes</ph>; <ph outputclass=\"caution\">elderly</ph>; <ph outputclass=\"caution\">parkinsonism</ph>; <ph outputclass=\"caution\">QT-interval prolongation</ph>; <ph outputclass=\"caution\">senile confusional states</ph>\r\n</p>\r\n </section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP60410\" outputclass=\"interactions\" rev=\"1.24\" parent=\"/drugs/flupentixol\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Avoid concomitant administration of drugs that prolong QT interval.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60370\" outputclass=\"sideEffects\" rev=\"1.23\" parent=\"/drugs/flupentixol\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Asthenia</ph>; <ph outputclass=\"sideEffect\">dyspnoea</ph>; <ph outputclass=\"sideEffect\">hypersalivation</ph>; <ph outputclass=\"sideEffect\">myalgia</ph>; <ph outputclass=\"sideEffect\">sudden death</ph>; <ph outputclass=\"sideEffect\">torsade de pointes</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>Less sedating but extrapyramidal symptoms frequent.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60397\" outputclass=\"pregnancy\" parent=\"/drugs/flupentixol\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid unless potential benefit outweighs risk.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p>\n<p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60527\" outputclass=\"breastFeeding\" parent=\"/drugs/flupentixol\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Present in breast milk&#8212;avoid.</p>\n<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant. <i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system. Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60451\" outputclass=\"hepaticImpairment\" parent=\"/drugs/flupentixol\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Can precipitate coma.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInHepaticImpairment\">\n<sectiondiv>\n<p>Consider serum-flupentixol concentration monitoring in hepatic impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60377\" outputclass=\"renalImpairment\" parent=\"/drugs/flupentixol\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Start with small doses of antipsychotic drugs in severe renal impairment because of increased cerebral sensitivity.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution in renal failure.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60388\" outputclass=\"patientAndCarerAdvice\" rev=\"1.7\" parent=\"/drugs/flupentixol\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Although drowsiness may occur, can also have an alerting effect so should not be taken in the evening.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP2220-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/flupentixol\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral solution, oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74957\" title=\"Tablet\" namespace=\"/drugs/flupentixol/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78155\" namespace=\"/treatment-summaries/psychoses-and-related-disorders\" title=\"Psychoses and related disorders\" count=\"2\" rel=\"backlink\">Psychoses and related disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78258\" namespace=\"/treatment-summaries/antidepressant-drugs\" title=\"Antidepressant drugs\" count=\"2\" rel=\"backlink\">Antidepressant drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_389\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/thioxanthenes/flupentixol\" title=\"Flupentixol\" count=\"1\" rel=\"link\">Flupentixol</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" namespace=\"/drug-classes/antipsychotic-drugs\" title=\"ANTIPSYCHOTIC DRUGS\" count=\"1\" rel=\"link\">ANTIPSYCHOTIC DRUGS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74957\" namespace=\"/drugs/flupentixol/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP2220",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/flupentixol",
    "basename": "flupentixol",
    "title": "FLUPENTIXOL",
    "interactants": [
        {
            "id": "bnf_int_389",
            "label": "Flupentixol"
        }
    ],
    "vtmid": "13314611000001107",
    "drugClassification": [
        "Antipsychotics (first-generation)"
    ],
    "inheritsFromClass": [
        "ANTIPSYCHOTIC DRUGS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "Flupenthixol"
    ],
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Schizophrenia and other psychoses, particularly with apathy and withdrawal but not mania or psychomotor hyperactivity",
                        "html": "Schizophrenia and other psychoses, particularly with apathy and withdrawal but not mania or psychomotor hyperactivity"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 3&#8211;9 mg twice daily, adjusted according to response, for debilitated patients, use elderly dose; maximum 18 mg per day.",
                        "html": "<p>Initially 3&#8211;9&#8239;mg twice daily, adjusted according to response, for debilitated patients, use elderly dose; maximum 18&#8239;mg per day.</p>"
                    },
                    {
                        "textContent": "Initially 0.75&#8211;4.5 mg twice daily, adjusted according to response.",
                        "html": "<p>Initially 0.75&#8211;4.5&#8239;mg twice daily, adjusted according to response.</p>",
                        "ageGroup": "elderly"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Depressive illness",
                        "html": "Depressive illness"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 1 mg once daily, dose to be taken in the morning, increased if necessary to 2 mg after 1 week, doses above 2 mg to be given in divided doses, last dose to be taken before 4 pm; discontinue if no response after 1 week at maximum dosage; maximum 3 mg per day.",
                        "html": "<p>Initially 1&#8239;mg once daily, dose to be taken in the morning, increased if necessary to 2&#8239;mg after 1&#8239;week, doses above 2&#8239;mg to be given in divided doses, last dose to be taken before 4 pm; discontinue if no response after 1 week at maximum dosage; maximum 3&#8239;mg per day.</p>"
                    },
                    {
                        "textContent": "Initially 500 micrograms daily, dose to be taken in the morning, then increased if necessary to 1 mg after 1 week, doses above 1 mg to be given in divided doses, last dose to be taken before 4 pm; discontinue if no response after 1 week at maximum dosage; maximum 1.5 mg per day.",
                        "html": "<p>Initially 500&#8239;micrograms daily, dose to be taken in the morning, then increased if necessary to 1&#8239;mg after 1&#8239;week, doses above 1&#8239;mg to be given in divided doses, last dose to be taken before 4 pm; discontinue if no response after 1 week at maximum dosage; maximum 1.5&#8239;mg per day.</p>",
                        "ageGroup": "elderly"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Circulatory collapse",
                "html": "Circulatory collapse"
            },
            {
                "type": "contraindications",
                "textContent": "CNS depression",
                "html": "CNS depression"
            },
            {
                "type": "contraindications",
                "textContent": "comatose states",
                "html": "comatose states"
            },
            {
                "type": "contraindications",
                "textContent": "excitable patients",
                "html": "excitable patients"
            },
            {
                "type": "contraindications",
                "textContent": "impaired consciousness",
                "html": "impaired consciousness"
            },
            {
                "type": "contraindications",
                "textContent": "overactive patients",
                "html": "overactive patients"
            },
            {
                "type": "contraindications",
                "textContent": "phaeochromocytoma",
                "html": "phaeochromocytoma"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Acute porphyrias",
                "html": "<xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            },
            {
                "type": "cautions",
                "textContent": "cardiac disorders",
                "html": "cardiac disorders"
            },
            {
                "type": "cautions",
                "textContent": "cardiovascular disease",
                "html": "cardiovascular disease"
            },
            {
                "type": "cautions",
                "textContent": "cerebral arteriosclerosis",
                "html": "cerebral arteriosclerosis"
            },
            {
                "type": "cautions",
                "textContent": "diabetes",
                "html": "diabetes"
            },
            {
                "type": "cautions",
                "textContent": "elderly",
                "html": "elderly"
            },
            {
                "type": "cautions",
                "textContent": "parkinsonism",
                "html": "parkinsonism"
            },
            {
                "type": "cautions",
                "textContent": "QT-interval prolongation",
                "html": "QT-interval prolongation"
            },
            {
                "type": "cautions",
                "textContent": "senile confusional states",
                "html": "senile confusional states"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Avoid concomitant administration of drugs that prolong QT interval.",
                "html": "<p>Avoid concomitant administration of drugs that prolong QT interval.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Asthenia",
                        "html": "Asthenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dyspnoea",
                        "html": "dyspnoea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypersalivation",
                        "html": "hypersalivation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "myalgia",
                        "html": "myalgia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "sudden death",
                        "html": "sudden death",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "torsade de pointes",
                        "html": "torsade de pointes",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "Less sedating but extrapyramidal symptoms frequent.",
                "html": "<p>Less sedating but extrapyramidal symptoms frequent.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid unless potential benefit outweighs risk.",
                "html": "<p>Avoid unless potential benefit outweighs risk.</p>"
            },
            {
                "type": "generalInformation",
                "textContent": "Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.\n\nFollowing maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.",
                "html": "<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Present in breast milk&#8212;avoid.\n\nThere is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant. Animal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system. Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.",
                "html": "<p>Present in breast milk&#8212;avoid.</p><p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant. <i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system. Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Can precipitate coma.",
                "html": "<p>Can precipitate coma.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "Consider serum-flupentixol concentration monitoring in hepatic impairment.",
                "html": "<p>Consider serum-flupentixol concentration monitoring in hepatic impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Start with small doses of antipsychotic drugs in severe renal impairment because of increased cerebral sensitivity.",
                "html": "<p>Start with small doses of antipsychotic drugs in severe renal impairment because of increased cerebral sensitivity.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution in renal failure.",
                "html": "<p>Manufacturer advises caution in renal failure.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Although drowsiness may occur, can also have an alerting effect so should not be taken in the evening.",
                "html": "<p>Although drowsiness may occur, can also have an alerting effect so should not be taken in the evening.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral solution",
                "oral suspension"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74957",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78155",
                "label": "Psychoses and related disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78258",
                "label": "Antidepressant drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_389",
                "label": "Flupentixol",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34569",
                "label": "ANTIPSYCHOTIC DRUGS",
                "type": "drugClass"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74957",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}